Thursday, January 27, 2022

COVID-19 drug

Optimus interim phase 3 data for Molnupiravir shows 78.3% efficacy

The interim results on 353 patients showed that the drug has been successful in reducing viral load effectively with RT-PCR negativity.

UoH Startup and INDRAS research proposes drug for Covid-19 treatment

The first result offering a safe, ready-to-use and cost-effective solution for Covid-19 treatment, Ertugliflozin is an FDA approved drug for type-2 diabetes.

Glenmark meeting surge in demand for Favipiravir

Exploring newer options for the management of Covid-19 and similar infectious diseases with focus on antifungals

DCGI approves anti-COVID drug developed by DRDO for emergency use

The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).

Latest News

- Advertisement -